Pharmaceutical Form:

Binosto^® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution.

Binosto^® (buffered alendronate sodium 70mg) is an easy-to-swallow, buffered oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, Binosto^® has the potential to improve long-term patient compliance and adherence to therapy, thereby decreasing the risk of disabling fractures.

Indication:

Europe: Treatment of osteoporosis in postmenopausal women. Binosto^® 70 mg reduces the risk of vertebral and hip fractures.

United States: Treatment of osteoporosis in postmenopausal women. Binosto^® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto^® is indicated for treatment to increase bone mass in men with osteoporosis.

Binosto^® is commercialized in the U.S.A. and selected European and Asian countries. EffRx is currently looking for Partners to commercialize Binosto^® in selected European countries, Latin America and the Asia-Pacific.

Please visit www.binosto.co.uk for the EU approved prescribing information.

For Business Development inquiries please contact: info@effrx.com.

Binosto^® is available by prescription in the United States to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

Visit www.binosto.com for U.S. approved prescribing information.